27760426|t|Cl-NQTrp Alleviates Tauopathy Symptoms in a Model Organism through the Inhibition of Tau Aggregation -Engendered Toxicity
27760426|a|Alzheimer's disease (AD) is the most abundant tauopathy and is characterized by Aβ -derived plaques and tau -derived tangles, resulting from the unfolding of the corresponding monomeric subunits into ordered β-sheet oligomers and fibrils. Intervening in the toxic aggregation process is a promising therapeutic approach, but, to date, a disease -modifying therapy is neither available for AD nor for other tauopathies. Along these lines, we have previously demonstrated that a small naphthoquinone-tryptophan hybrid, termed NQTrp, is an effective modulator of tauopathy in vitro and in vivo. However, NQTrp is difficult to synthesize and is not very stable. Therefore, we tested whether a more stable and easier-to-synthesize modified version of NQTrp, containing a Cl ion, namely Cl-NQTrp, is also an effective inhibitor of tau aggregation in vitro and in vivo. Cl-NQTrp was previously shown to efficiently inhibit the aggregation of various amyloidogenic proteins and peptides. We demonstrate that Cl-NQTrp inhibits the in vitro assembly of PHF6, the aggregation -prone fragment of tau, and alleviates tauopathy symptoms in a transgenic Drosophila model through the inhibition of tau aggregation -engendered toxicity. These results suggest that Cl-NQTrp could be a unique potential therapeutic for AD since it targets aggregation of both Aβ and tau.
27760426	0	8	Cl-NQTrp	T103	UMLS:C3501592
27760426	20	29	Tauopathy	T038	UMLS:C0949664
27760426	30	38	Symptoms	T033	UMLS:C1457887
27760426	44	58	Model Organism	T038	UMLS:C0012644
27760426	85	88	Tau	T103	UMLS:C0085401
27760426	89	100	Aggregation	T038	UMLS:C3850147
27760426	113	121	Toxicity	T037	UMLS:C0600688
27760426	122	141	Alzheimer's disease	T038	UMLS:C0002395
27760426	143	145	AD	T038	UMLS:C0002395
27760426	168	177	tauopathy	T038	UMLS:C0949664
27760426	214	221	plaques	T017	UMLS:C0333463
27760426	226	229	tau	T103	UMLS:C0085401
27760426	239	246	tangles	T038	UMLS:C0085400
27760426	267	276	unfolding	T038	UMLS:C1655065
27760426	298	316	monomeric subunits	T103	UMLS:C0599220
27760426	330	337	β-sheet	T082	UMLS:C0162806
27760426	352	359	fibrils	T017	UMLS:C0225328
27760426	361	372	Intervening	T058	UMLS:C0184661
27760426	386	397	aggregation	T038	UMLS:C3850147
27760426	421	441	therapeutic approach	T058	UMLS:C0087111
27760426	459	466	disease	T038	UMLS:C0012634
27760426	478	485	therapy	T058	UMLS:C0087111
27760426	511	513	AD	T038	UMLS:C0002395
27760426	528	539	tauopathies	T038	UMLS:C0949664
27760426	605	637	naphthoquinone-tryptophan hybrid	T103	UMLS:C3711678
27760426	646	651	NQTrp	T103	UMLS:C3711678
27760426	682	691	tauopathy	T038	UMLS:C0949664
27760426	705	712	in vivo	T082	UMLS:C1515655
27760426	723	728	NQTrp	T103	UMLS:C3711678
27760426	763	778	not very stable	T033	UMLS:C0443343
27760426	868	873	NQTrp	T103	UMLS:C3711678
27760426	888	894	Cl ion	T103	UMLS:C0596019
27760426	903	911	Cl-NQTrp	T103	UMLS:C3501592
27760426	947	950	tau	T103	UMLS:C0085401
27760426	951	962	aggregation	T038	UMLS:C3850147
27760426	976	983	in vivo	T082	UMLS:C1515655
27760426	985	993	Cl-NQTrp	T103	UMLS:C3501592
27760426	1042	1053	aggregation	T038	UMLS:C3850147
27760426	1065	1087	amyloidogenic proteins	T103	UMLS:C1456454
27760426	1092	1100	peptides	T103	UMLS:C0030956
27760426	1122	1130	Cl-NQTrp	T103	UMLS:C3501592
27760426	1165	1169	PHF6	T103	UMLS:C1335533
27760426	1175	1186	aggregation	T038	UMLS:C3850147
27760426	1194	1202	fragment	T103	UMLS:C1335533
27760426	1206	1209	tau	T103	UMLS:C0085401
27760426	1226	1235	tauopathy	T038	UMLS:C0949664
27760426	1236	1244	symptoms	T033	UMLS:C1457887
27760426	1250	1260	transgenic	T204	UMLS:C0003069
27760426	1261	1271	Drosophila	T204	UMLS:C0013138
27760426	1272	1277	model	T038	UMLS:C1519606
27760426	1304	1307	tau	T103	UMLS:C0085401
27760426	1308	1319	aggregation	T038	UMLS:C3850147
27760426	1332	1340	toxicity	T037	UMLS:C0600688
27760426	1369	1377	Cl-NQTrp	T103	UMLS:C3501592
27760426	1422	1424	AD	T038	UMLS:C0002395
27760426	1442	1453	aggregation	T038	UMLS:C3850147
27760426	1469	1472	tau	T103	UMLS:C0085401